KR20010102239A - 약물 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물 - Google Patents
약물 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물 Download PDFInfo
- Publication number
- KR20010102239A KR20010102239A KR1020017010490A KR20017010490A KR20010102239A KR 20010102239 A KR20010102239 A KR 20010102239A KR 1020017010490 A KR1020017010490 A KR 1020017010490A KR 20017010490 A KR20017010490 A KR 20017010490A KR 20010102239 A KR20010102239 A KR 20010102239A
- Authority
- KR
- South Korea
- Prior art keywords
- drug
- deoxypeganine
- treatment
- drug dependence
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 title claims abstract description 55
- VARHXCYGZKSOOO-UHFFFAOYSA-N Deoxyvasicinone Natural products C1=CC=C2C(=O)N(CCC3)C3=NC2=C1 VARHXCYGZKSOOO-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 206010013663 drug dependence Diseases 0.000 title claims abstract description 23
- 208000011117 substance-related disease Diseases 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 13
- 239000002552 dosage form Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 abstract description 4
- 238000013270 controlled release Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000556 agonist Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- -1 flow improvers Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000004821 Contact adhesive Substances 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 240000005523 Peganum harmala Species 0.000 description 1
- 235000005126 Peganum harmala Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011140 metalized polyester Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906978A DE19906978B4 (de) | 1999-02-19 | 1999-02-19 | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
| DE19906978.6 | 1999-02-19 | ||
| PCT/EP2000/000974 WO2000048582A2 (de) | 1999-02-19 | 2000-02-08 | Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der drogenabhängigkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010102239A true KR20010102239A (ko) | 2001-11-15 |
Family
ID=7898024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017010490A Ceased KR20010102239A (ko) | 1999-02-19 | 2000-02-08 | 약물 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6599511B1 (https=) |
| EP (1) | EP1152763B1 (https=) |
| JP (1) | JP2002537246A (https=) |
| KR (1) | KR20010102239A (https=) |
| AT (1) | ATE228843T1 (https=) |
| AU (1) | AU3278800A (https=) |
| DE (2) | DE19906978B4 (https=) |
| DK (1) | DK1152763T3 (https=) |
| ES (1) | ES2188513T3 (https=) |
| WO (1) | WO2000048582A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230080978A (ko) * | 2021-11-30 | 2023-06-07 | 이화여자대학교 산학협력단 | 데옥시바시시논을 유효성분으로 포함하는 미백용 조성물 및 상기 데옥시바시시논 제조방법 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119863A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen |
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| DE10163667B4 (de) * | 2001-12-21 | 2006-10-26 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression |
| DE10304141B4 (de) | 2003-02-03 | 2006-03-09 | Hf Arzneimittelforschung Gmbh | Verfahren zur Herstellung von Chinazolin-Alkaloiden |
| DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
| DE10354893B4 (de) * | 2003-11-24 | 2011-03-10 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen |
| RU2460515C1 (ru) * | 2011-10-17 | 2012-09-10 | Тагир Рафаилович Гизатуллин | Способ дезинтоксикационно-инфузионного лечения больных при употреблении дезоморфина |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU605614A1 (ru) * | 1971-10-20 | 1978-05-05 | Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср | Антихолинэстеразное средство |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| US5591738A (en) * | 1994-10-14 | 1997-01-07 | Nda International, Inc. | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
-
1999
- 1999-02-19 DE DE19906978A patent/DE19906978B4/de not_active Expired - Fee Related
-
2000
- 2000-02-08 US US09/889,648 patent/US6599511B1/en not_active Expired - Fee Related
- 2000-02-08 EP EP00910649A patent/EP1152763B1/de not_active Expired - Lifetime
- 2000-02-08 JP JP2000599374A patent/JP2002537246A/ja not_active Abandoned
- 2000-02-08 ES ES00910649T patent/ES2188513T3/es not_active Expired - Lifetime
- 2000-02-08 AT AT00910649T patent/ATE228843T1/de not_active IP Right Cessation
- 2000-02-08 WO PCT/EP2000/000974 patent/WO2000048582A2/de not_active Ceased
- 2000-02-08 KR KR1020017010490A patent/KR20010102239A/ko not_active Ceased
- 2000-02-08 DE DE50000864T patent/DE50000864D1/de not_active Expired - Fee Related
- 2000-02-08 DK DK00910649T patent/DK1152763T3/da active
- 2000-02-08 AU AU32788/00A patent/AU3278800A/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230080978A (ko) * | 2021-11-30 | 2023-06-07 | 이화여자대학교 산학협력단 | 데옥시바시시논을 유효성분으로 포함하는 미백용 조성물 및 상기 데옥시바시시논 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2188513T3 (es) | 2003-07-01 |
| WO2000048582A3 (de) | 2001-04-12 |
| WO2000048582A2 (de) | 2000-08-24 |
| EP1152763B1 (de) | 2002-12-04 |
| US6599511B1 (en) | 2003-07-29 |
| DE50000864D1 (de) | 2003-01-16 |
| AU3278800A (en) | 2000-09-04 |
| DE19906978A1 (de) | 2000-08-24 |
| JP2002537246A (ja) | 2002-11-05 |
| DE19906978B4 (de) | 2004-07-08 |
| ATE228843T1 (de) | 2002-12-15 |
| EP1152763A2 (de) | 2001-11-14 |
| DK1152763T3 (da) | 2003-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6974588B1 (en) | Transdermal patch for delivering volatile liquid drugs | |
| US5186939A (en) | Laminated composite for transdermal administration of fentanyl | |
| KR101454362B1 (ko) | 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제 | |
| KR950001968B1 (ko) | 펜타닐의 경피투여용 적층 혼성체 | |
| KR100483476B1 (ko) | 이중 점착제 경피 약물전달체계 | |
| EP1137406B1 (en) | Transdermal patch for delivering volatile liquid drugs | |
| KR100893158B1 (ko) | 경피성 그라니세트론 | |
| RU2713207C2 (ru) | Трансдермальная композиция, содержащая донепезил в качестве активного ингредиента | |
| CN103313705A (zh) | 含有利凡斯的明的经皮吸收制剂 | |
| US8246981B2 (en) | Transdermal method and patch for emesis | |
| IL159345A (en) | Combining an active ingredient in pharmacological addictive substances or in the treatment of a toxic substance | |
| KR20010102239A (ko) | 약물 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물 | |
| CZ289395A3 (en) | Transdermic therapeutic system for administration of serotonin agonists | |
| WO1996025154A1 (en) | Transdermal formulation | |
| US5068103A (en) | Salbutamol-containing plaster and method of producing same | |
| HU220045B (hu) | Pilokarpin szabályozott leadására alkalmas transzdermális rendszer és eljárás előállítására | |
| KR20130022602A (ko) | 경피 흡수 제제 및 그 제조방법 | |
| EP1404341B1 (de) | Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit | |
| EP1449527A2 (en) | Transdermal patch for administering a volatile liquid drug | |
| CN1140990A (zh) | 用于防止不希望的宫缩的硝化甘油经皮给药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20010817 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20020705 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050110 Comment text: Request for Examination of Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20050719 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060627 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20060913 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060627 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |